AOD-9604 (Anti-Obesity Drug 9604)
Also Known AsAOD 9604 · Tyr-hGH Fragment 177-191 · hGH Fragment
Developed by Frank Ng and colleagues at Monash University, Melbourne, Australia as a modified fragment of human growth hormone (amino acids 177-191). The fragment was identified as the lipolytic region of hGH, with the addition of a tyrosine residue at the N-terminus improving stability and receptor binding without stimulating IGF-1 or exhibiting growth-promoting effects.
How AOD-9604 Works
Beta-3 Adrenergic Receptor Pathway
AOD-9604 mimics the lipolytic mechanism of hGH by stimulating beta-3 adrenergic receptors in adipose tissue, triggering hormone-sensitive lipase (HSL) activation and subsequent triglyceride hydrolysis. Unlike full hGH, it does not activate the JAK2/STAT5 growth pathway.
Anti-Lipogenic Activity
Inhibits lipogenesis (fat formation) by suppressing key lipogenic enzymes including fatty acid synthase and acetyl-CoA carboxylase. This dual action (promoting fat breakdown while preventing fat formation) distinguishes it from compounds that only affect one side of the equation.
Cartilage Regeneration
Emerging research demonstrates chondroprotective and regenerative effects. AOD-9604 stimulates proteoglycan and collagen synthesis in cartilage tissue, promoting extracellular matrix production in osteoarthritic joints.
Published Research
Obesity & Fat Metabolism
ModeratePhase 2 clinical trials demonstrated dose-dependent weight loss over 12 weeks in obese subjects without affecting IGF-1 levels or causing diabetogenic effects. Animal studies consistently show reduction in body fat without affecting lean mass. AOD-9604 received GRAS (Generally Recognized As Safe) status from the US FDA in 2014.
Osteoarthritis & Cartilage Repair
ModeratePreclinical studies demonstrate stimulation of cartilage repair via enhanced proteoglycan synthesis. A proprietary formulation (i-Body) has completed Phase 2 clinical trials for knee osteoarthritis showing improved pain scores and function. Mechanism is distinct from its metabolic effects.
Growth Hormone Dissociation
StrongAOD-9604 is a key research tool for understanding which domains of human growth hormone are responsible for different biological effects. It demonstrates that the lipolytic, anti-lipogenic, and chondroprotective actions of hGH can be isolated from its growth-promoting and diabetogenic effects.
Safety Profile
AOD-9604 received GRAS (Generally Recognized As Safe) status from the US FDA in 2014 for use as a food ingredient. Phase 2 clinical trials reported no significant adverse effects versus placebo. Key safety advantage: does not affect IGF-1, glucose homeostasis, or growth parameters, eliminating the metabolic risks associated with full hGH.
Handling & Storage
Reconstitute with bacteriostatic water. AOD-9604 is a stable peptide fragment with good aqueous solubility. Store reconstituted solution at 2-8°C. Lyophilized powder stable at -20°C for 24+ months.
Peer-Reviewed Literature
- 1
Increase of fat oxidation and weight loss in obese mice by chronic treatment with human growth hormone or a modified C-terminal fragment
Heffernan MA, Thorburn AW, Fam B, et al.
- 2
Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone
Ng FM, Sun J, Sharma L, et al.
- 3
Safety and tolerability of the hexadecapeptide AOD9604 in humans
Stier H, Vos E, Kenley D.
Journal of Endocrinology and Metabolism, 2013
AOD-9604 FAQ
What is AOD-9604?
AOD-9604 (Anti-Obesity Drug 9604) is a modified fragment of human growth hormone consisting of amino acids 177-191 with an additional N-terminal tyrosine. It was designed to retain the fat-metabolizing properties of growth hormone while eliminating its growth-promoting and diabetogenic effects. It received FDA GRAS status in 2014.
How is AOD-9604 different from HGH?
AOD-9604 is a small fragment (16 amino acids) of the full 191-amino-acid hGH molecule. It retains the lipolytic (fat-burning) and anti-lipogenic (fat-formation-preventing) activities but does NOT stimulate IGF-1, does not promote growth, and does not cause insulin resistance — eliminating the major safety concerns of full growth hormone.
Does AOD-9604 have FDA status?
Yes. In 2014, AOD-9604 received GRAS (Generally Recognized As Safe) status from the US FDA for use as a food ingredient. This is not a drug approval but confirms safety for human consumption at food-grade levels. Research-grade AOD-9604 is sold for investigational use only.
AOD-9604 Products
All compounds 99%+ purity, verified by Janoshik Analytical. GMP-manufactured lyophilized powder.
AOD 9604
5mgThe fat-burning fragment of growth hormone — targets and destroys stubborn body fat (especially belly fat) without touching muscle, blood sugar, or hormone levels.
- Burns fat without affecting blood sugar or growth hormone levels
- Targets stubborn belly fat specifically
Explore Related Research
The weight loss revolution — the same molecule in Ozempic that helps millions lose 15-20% of body weight by silencing food cravings and resetting appetite at the brain level.
- Lose 15-20% of body weight without willpower or starvation
- Completely eliminates food noise and constant cravings
5-Amino-1MQ
50mg × 60 CapsulesBurns fat at the cellular level — blocks the enzyme that makes fat cells expand, shrinking them while you keep eating normally.
- Shrinks fat cells without changing your diet
- Blocks the enzyme (NNMT) that makes fat cells grow
MOTS-c
10mgExercise in a molecule — activates your metabolism, burns fat without dieting, and gives your cells the energy boost of a hard workout.
- Burns fat by activating your body's metabolic furnace (AMPK)
- Mimics the benefits of exercise at the cellular level
Disclaimer: This monograph is provided for educational and research purposes only. G26x Peptides products are sold exclusively as research chemicals. They are not intended for human consumption, therapeutic use, or as dietary supplements. All research should be conducted in compliance with applicable laws and institutional review board protocols. Information presented here is sourced from published peer-reviewed literature and does not constitute medical advice.